Drug intelligence / Profile preview

IgYGate F

Development stage: Unknown
Lead developer: EW Nutrition Japan
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

IgYGate F is an oral dietary supplement formulated as lozenges, developed by the Immunology Research Institute in Gifu and EW Nutrition, and distributed in Vietnam by Dong Do Pharmaceutical. The active ingredient is Ovalgen F (also known as Ovalgen FL), which consists of specific chicken egg yolk immunoglobulins (IgY) targeting influenza viruses, including influenza A (H1N1, H3N2, H5N1) and influenza B. IgYGate F acts locally in the oral cavity and throat to bind and neutralize viral pathogens, preventing them from adhering to and invading host mucosal cells. It is used to support the immune system, strengthen resistance against seasonal respiratory infections, and reduce flu-like symptoms.

Brand names: IgYGate F
Other names: Ovalgen FOvalgen FL

Targets

NeuraminidaseHA (Hemagglutinin)

Beyond the preview

Go deeper on IgYGate F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgYGate F.

Explore the full profile